Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 258 results found since Jan 2013.

Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition augments recirculation of the low-density lipoprotein (LDL) receptor to the hepatocyte surface [1], thereby lowering atherogenic particles through accelerated clearance of circulating LDL cholesterol (LDL-C). This observation led to several strategies to inhibit PCSK9, including monoclonal antibodies (evolocumab and alirocumab), small-molecule inhibitors specific to PCSK9, small interfering RNA (siRNA) molecules (inclisiran), antisense oligonucleotides, immunotherapy with a PCSK9 peptide vaccine, and CRISPR/Cas9 editing of PCSK9.
Source: Atherosclerosis - October 21, 2022 Category: Cardiology Authors: Maya S. Safarova, Iftikhar J. Kullo Tags: Editorial Source Type: research

Cancers, Vol. 14, Pages 5363: Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination
i Marco Benazzo Squamous cell carcinoma is the most common malignancy that arises in the head-and-neck district. Traditional treatment could be insufficient in case of recurrent and/or metastatic cancers; for this reason, more selective and enhanced treatments are in evaluation in preclinical and clinical trials to increase in situ concentration of chemotherapy drugs promoting a selectively antineoplastic activity. Among all cancer treatment types (i.e., surgery, chemotherapy, radiotherapy), electroporation (EP) has emerged as a safe, less invasive, and effective approach for cancer treatment. Reversible EP, using an...
Source: Cancers - October 31, 2022 Category: Cancer & Oncology Authors: Silvia Pisani Giulia Bertino Adriele Prina-Mello Laura Deborah Locati Simone Mauramati Ida Genta Rossella Dorati Bice Conti Marco Benazzo Tags: Review Source Type: research

PAIP2 is a potential diagnostic and prognostic biomarker of breast cancer and is associated with immune infiltration
Breast cancer is the second highest incidence of cancer in the world. It is of great significance to find biomarkers to diagnose breast cancer and predict the prognosis of breast cancer patients. PAIP2 is a poly (A) -binding protein interacting protein that regulates the expression of VEGF. However, the possible role of PAIP2 in the progression of breast cancer is still unknown. RT-qRCR and Western blotting were used to verify the expression of PAIP2 in breast cancer cells and normal breast cells. The data of breast cancer samples were obtained in the TCGA database and the HPA database to analyze the expression of PAIP2 in...
Source: Frontiers in Genetics - November 10, 2022 Category: Genetics & Stem Cells Source Type: research

p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target
CONCLUSION: Our research may provide a novel potential target for TNBC.PMID:36352176 | DOI:10.1007/s11033-022-08047-z
Source: Molecular Biology Reports - November 9, 2022 Category: Molecular Biology Authors: Siyu Deng Mengna Wang Chenglong Wang Yan Zeng Xue Qin Yiwen Tan Bing Liang Youde Cao Source Type: research

Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy
Adv Drug Deliv Rev. 2022 Nov 23:114624. doi: 10.1016/j.addr.2022.114624. Online ahead of print.ABSTRACTThe development of carrier systems that are able to transport and release therapeutics to target cells is an emergent strategy to treat cancer; however, they following endocytosis are usually trapped in the endo/lysosomal compartments. The efficacy of drug conjugates and nanotherapeutics relies critically on their intracellular drug release ability, for which advanced systems responding to the unique lysosomal environment such as acidic pH and abundant enzymes (e.g. cathepsin B, sulfatase and β-glucuronidase) or equipped...
Source: Advanced Drug Delivery Reviews - November 26, 2022 Category: Drugs & Pharmacology Authors: Yinping Sun Yongjie Sha Guanhong Cui Fenghua Meng Zhiyuan Zhong Source Type: research

Extracellular vesicles (EVs) as diagnostic tools in the phenotypic determination of lung tumors
Immunotherapy has been one of the great advances in recent years for the treatment of advanced tumors. Our goal is to determine whether extracellular vesicles (EVs) are effective and appropriate tools for detecting and blocking immune checkpoints proteins (ICPs). We developed a method for tracing tumor content via an analysis of EVs surface makers in the bloodstream using the MAGPIX platform (Fig.1). As a proof of concept, we have developed the detection of 4 ICP-EV. We will use this technology to monitor the ICP-EV profile in patients undergoing immunotherapeutic treatment. Second, endothelial EVs will be used as drug car...
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Cambier, M., Muller, F., Henket, M., Remacle, C., Guiot, J., Struman, I. Tags: 11.01 - Lung cancer Source Type: research

Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
Source: Pharmaceutical Research - December 7, 2022 Category: Drugs & Pharmacology Source Type: research

DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy
CONCLUSION: Our data show that DKK1 can affect both radiotherapy and immunotherapy in HNSC, suggesting that DKK1 can be a potential target for radioimmunology in HNSC.PMID:36690301 | DOI:10.1016/j.radonc.2023.109485
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - January 23, 2023 Category: Radiology Authors: Xinyu Ye Jingwen Liu Rencui Quan Yi Lu Jian Zhang Source Type: research